| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2004 ( Subtotal = $449,054 ) |
| | 2004 | 2004 | SERENIX PHARMACEUTICALS | 111 RESEARCH DRIVE B217 | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R44MH063663 | A POTENTIAL NEW DRUG FOR DEPRESSION | 000 | 2 | NIH | 8/31/2004 | $449,054 |
|
| Issue Date FY: 2003 ( Subtotal = $248,665 ) |
| | 2003 | 2003 | SERENIX PHARMACEUTICALS | 111 RESEARCH DRIVE B217 | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R42HD037290 | TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION | 000 | 3 | NIH | 6/18/2003 | $248,665 |
|
| Issue Date FY: 2002 ( Subtotal = $350,019 ) |
| | 2002 | 2002 | SERENIX PHARMACEUTICALS | 111 RESEARCH DRIVE B217 | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R42HD037290 | TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION | 000 | 2 | NIH | 7/1/2002 | $250,019 |
| | 2002 | 2002 | SERENIX PHARMACEUTICALS | 111 RESEARCH DRIVE B217 | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R41MH063663 | A NEW DRUG FOR DEPRESSION | 000 | 1 | NIH | 2/13/2002 | $100,000 |
|
| Issue Date FY: 2000 ( Subtotal = $100,000 ) |
| | 2000 | 2000 | SERENIX PHARMACEUTICALS | 111 RESEARCH DRIVE B217 | BETHLEHEM | PA | 18015 | NORTHAMPTON | USA | R41HD037290 | TREATING SELF-ABUSE IN AUTISM AND MENTAL RETARDATION | 000 | 1 | NIH | 4/14/2000 | $100,000 |
|
|
